NCT05757219 2026-02-27
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
9 trialsNCT05621096 2025-09-25
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
Phase 1 Active not recruiting
NCT05507827 2025-09-16
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Stanford University
Phase 1 Active not recruiting
NCT05281809 2025-01-13
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 2 Recruiting
NCT04650451 2023-04-20
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Bellicum Pharmaceuticals
Phase 1 Suspended
NCT03049449 2023-01-18
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03958656 2021-09-09
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02215967 2019-10-08
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00924287 2015-10-28
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated